Don Kania Net Worth

The estimated Net Worth of Don R Kania is at least $5.36 Thousand dollars as of 31 July 2019. Don Kania owns over 215 units of NanoString Technologies stock worth over $5,356 and over the last 15 years he sold NSTG stock worth over $0. In addition, he makes $0 as Director at NanoString Technologies.

Don Kania NSTG stock SEC Form 4 insider trading

Don has made over 1 trades of the NanoString Technologies stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 215 units of NSTG stock worth $5,356 on 31 July 2019.

The largest trade he’s ever made was exercising 215 units of NanoString Technologies stock on 31 July 2019 worth over $5,356. On average, Don trades about 18 units every 0 days since 2004. As of 31 July 2019 he still owns at least 215 units of NanoString Technologies stock.

You can see the complete history of Don Kania stock trades at the bottom of the page.

Don Kania biography

Dr. Don R. Kania, Ph.D., is Director of the Company. Kania, has more than 25 years of experience in scientific research and development, global operations, and manufacturing. Most recently, Kania served as CEO, president and member of the board of directors of FEI Company for 10 years until its 2016 acquisition by Thermo Fisher Scientific Inc. Kania also held various positions at Veeco Instruments Inc., ultimately as chief operating officer. Prior to that he held technical and general management positions of increasing responsibility at Lawrence Livermore National Laboratory and Los Alamos National Laboratory. Kania currently serves on the board of directors of Intuitive Surgical, a publicly-traded leader in minimally invasive care and robotic-assisted surgery. He previously served as a board member of Aldevron LLC, the leading global supplier of plasmid DNA used in gene therapies, and of American Science and Engineering Inc., a leading manufacturer of X-ray imaging equipment. He is also on the Board of Trustees of the Oregon Health & Science University Foundation, the board of the Oregon Shakespeare Festival and he serves as an advisor to several privately held life sciences companies. He holds B.S., M.S. and Ph.D. degrees in physics and engineering from the University of Michigan.

How old is Don Kania?

Don Kania is 64, he’s been the Director of NanoString Technologies since 2019. There are 1 older and 11 younger executives at NanoString Technologies. The oldest executive at NanoString Technologies, Inc. is William Young, 74, who is the Independent Chairman of the Board.

What’s Don Kania’s mailing address?

Don’s mailing address filed with the SEC is C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE N, SEATTLE, WA, 98109.

Insider trading at NanoString Technologies

Over the last 6 years, insiders at NanoString Technologies have traded over $95,787,093 worth of NanoString Technologies stock and bought 780,000 units worth $7,707,300 . The most active insider traders include Charles P Jr Waite, Lifesciences Ii, L.P.Clarus…, and Nicholas Galakatos. On average, NanoString Technologies executives and independent directors trade stock every 35 days with the average trade being worth of $2,381,944. The most recent stock trade was executed by Kirk Malloy on 15 October 2019, trading 1,000 units of NSTG stock currently worth $7,470.

What does NanoString Technologies do?

NanoString Technologies, Inc. engages in the provision of life science tools for translational research and molecular diagnostic products. It offers analysis solutions, gene expression panels, protein assays, DNA Assaya, miRNA assays, vantage 3D assays, custom solutions, sample prep and nCounter consumables, and nDesign gateway. The company was founded by Amber Ratcliffe, Krassen Dimitrov, and Dwayne Dunaway on June 20, 2003 and is headquartered in Seattle, WA.

What does NanoString Technologies’s logo look like?

Complete history of Don Kania stock trades at Intuitive Surgical, NanoString Technologies, and Veeco Instruments

NanoString Technologies executives and stock owners

NanoString Technologies executives and other stock owners filed with the SEC include:

  • R. Bradley Gray, President, Chief Executive Officer, Director
  • K. Thomas Bailey, Chief Financial Officer, Treasurer
  • Joseph Beechem, Senior Vice President – Research and Development
  • David Ghesquiere, Senior Vice President – Corporate & Business Development
  • J. Chad Brown, Senior Vice President – Sales and Marketing
  • Mary Allen, Senior Vice President – Operations and Administration
  • William Young, Independent Chairman of the Board
  • Gregory Norden, Independent Director
  • Charles Waite, Independent Director
  • Elisha Finney, Independent Director
  • Kirk Malloy, Independent Director
  • Robert Hershberg, Independent Director
  • Don Kania, Director
  • Mark Winham, Senior Vice President of Operations
  • Nicholas Galakatos, Director
  • Lifesciences Ii, L.P.Clarus…,
  • Wayne Burns, SVP, Operations & Admin
  • James A Johnson, Chief Financial Officer
  • Lifesciences Ii, L.P.Clarus…,
  • Barney Saunders, SVP & GM, Life Sciences
  • Venture Partners Vi Lpovp V…,
  • Fisher Jurvetson Fund Vii, …,
  • Finny Kuruvilla, Director
  • Fisher Jurvetson Fund Vii, …,
  • Tina Susan Nova, Director
  • Bruce J. Seeley, SVP & GM, Diagnostics
  • J Wayne Cowens, Chief Medical Officer
  • Jennifer Scott Fonstad, Director
  • Bradford Crutchfield, Director